Abstract Library

#2266 Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors

Introduction: Several inflammatory response materials could be used for prediction of prognosis in cancer patients. The neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), thrombocytosis (the platelets number >400*103/mm3) have been introduced for prognostic scoring system in various cancers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: croitoru A

Authors: Grigorescu R, Croitoru A, Stanel I, Gheorghe C, Grama I,

Keywords: prognostic factors, survival,

#1782 Small Cell Metastatic Ascending Colon Neuroendocrine Carcinoma

Introduction: Poorly differentiated neuroendocrine carcinoma (NEC) of the gastrointestinal tract are rare malignant tumors with a poor prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Croitoru A

Authors: Croitoru A, Dinu I, Herlea V, Becheanu G, Dima S,

Keywords: Chemotherapy, metastases,

#1781 Clinical Characteristics and Treatment Outcome of Advanced G3 Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)- A Retrospective Analysis

Introduction: Advanced poorly differentiated GEP-NEC are uncommon neoplasms and treated mainly with platinum-based chemotherapy associated with etoposide.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Croitoru A

Authors: Grigorescu R, Stanel I, Gramaticu I, Dinu I, Buica F,

Keywords: GEP-NEC, chemotherapy, prognostic factors,

#1779 Large Cell Metastatic Pancreatic Neuroendocrine Carcinoma Treated with Somatostatin Analogues

Introduction: Poorly differentiated neuroendocrine carcinoma of the pancreas are rare malignant tumors with a poor prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Croitoru A

Authors: Croitoru A, Dinu I, Herlea V, Becheanu G, Grasu M,

Keywords: carcinoid syndrome, somatostatin analogues,

#1774 Report on the Clinicopathological Characteristics of 548 Romanian Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs

Introduction: In Romania, treatment with somatostatin analogs (SSA) for neuroendocrine tumors (NETs) is based on the National Clinical Practice Guideline for the Diagnostic and Treatment of NETs and is reimbursed by the National Health Insurance Company since 2008.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Fica S, Ghemigian A, Ghervan C, Croitoru A, Pirvulescu I,

Keywords: neuroendocrine tumors, somatostatin analogs,